TMCnet News
XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer StudyAUSTIN, Texas, Feb. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that an Independent Data Monitoring Committee (IDMC) has performed a prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company’s novel candidate antibody therapy for colorectal cancer. The IDMC reported that the FDA Fast-Tracked study had no safety concerns and that indications of efficacy were sufficient to recommend proceeding with the study without modification. Dr. George Fisher, Professor of Medicine, Stanford Cancer Center, and global Chair of the XCITE study, commented, “We are grateful to the IDMC members for their diligent review of the Phase 3 data. The go-ahead to continue on with our study after this substantial review of safety and efficacy is encouraging and we look forward to that next analysis as the data mature.” These findings also lend support to the Company’s recently completed Phase 3 study in Europe, which used a novel primary endpoint to evaluate efficacy for the same antibody therapy for the treatment of advanced colorectal cancer. The Chair of the European study and Professor of Medicine, Bournemouth University, UK, Dr. Tamas Hickish stated, “I am not surprised with these findings since we have seen such a strong connection with survival in patients that achieved the primary outcome in the European study.” According to the IDMC charter, this was the first of two interim efficacy analyses planned prior to the final analysis for overall survival. As determined based on alpha spending function of O’Brien and Fleming sequential group design (O’Brien PC, Fleming TR, 1979), survival analyses are to be performed after 276 (50%), 414 (75%) and 552 (100%) events at the respective stages. The criteria for early termination for efficacy (rejection of null hypothesis) or to accept the null hypothesis is based on the group sequential design. If the test statistics crosses the pre-specified boundaries for type I error (alpha cut-off 0.0029, 0.0121, and 0.025 at the first, second interim or final analysis, respectively) the trial will stop for efficacy. Otherwise the trial continues to the next stage. The cumulative p value for the acceptance boundary (beta) will be 0.25 and 0.08 at the first and second interim, respectively. If efficacy is established at an interim analysis, enrolment will be stopped and the control group will be allowed to crossover. All subjects will be followed up until death, loss to follow-up, or termination of the study. The decision rule with interim monitoring was planned as follows: If type I error probability (alpha) = the above specified cumulative alpha level at the given stage, trial will stop for efficacy; if the p value = the above specified beta levels, the trial will stop for accepting null hypothesis; if neither of these occurs, the trial will continue to the next stage. At final analysis, if alpha is =0.025 then efficacy will be declared, otherwise the null hypothesis will be accepted. Patients enrolled in the XCITE study were randomized 2:1 to receive Xilonix or placebo plus, in each case, best supportive care. Advanced colorectal cancer patients are required to have previous failed regimens that included flouropyrimidines, oxaliplatin, irinotecan, and Cetuximab (or Panitumumab for patients with KRAS mutation). Patients are expected to continue in the study until there is evidence of radiographic progression. The study may be stopped for efficacy or futility at the second remaining interim analysis, and patients are otherwise followed for up to 18 months in order to determine overall survival. The study is powered for 552 events at conclusion. The primary endpoint of this study is overall survival, with secondary endpoints including objective response rate, progression free survival, change in lean body mass and patient reported quality of life measures. About True Human™ Therapeutic Antibodies About XBiotech Cautionary Note on Forward-Looking Statements Contact Ashley Otero [email protected] 512-386-2930 |